
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc demonstrated a robust financial performance, highlighted by a gross margin of 71.6%, which represents a significant year-over-year increase of 980 basis points and exceeds market consensus. The company's revenue from Light Adjustable Lens (LAL) reached $28.5 million, marking a 60% increase, while revenue from the Light Delivery Device (LDD) was reported at $10.7 million, reflecting a 7% growth, both of which align closely with consensus estimates. Additionally, RxSight is expected to sustain double-digit growth fueled by increasing utilization rates and an expanding LDD installed base, positioning the company favorably for continued margin improvement.
Bears say
RxSight Inc. is experiencing a notable slowdown in its business performance, as evidenced by the deceleration in Light Adjustable Lens (LAL) utilization growth, which fell to +9% year-over-year in 4Q24, down from the previous growth range of +17%-22%. The company is facing challenging conditions in the U.S. cataract end market, with indications that U.S. intraocular lens sales may be flat or declining, which raises concerns about the sustainability of its market share amidst increased competition and a weakening macroeconomic environment. Furthermore, the downward revisions to earnings per share estimates for 2025 and 2026, as well as risks related to adoption hurdles and potential dilutive financing, contribute to a more negative outlook on RxSight's stock performance.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares